

slan⁺-monocytes/slan⁺-macrophages mediate a prominent CD20-dependent B cell lymphoma elimination via ADCC and ADCP

William Vermi^{1,2*}, Alessandra Micheletti^{3#}, Giulia Finotti³, Cristina Tecchio⁴, Federica Calzetti³, Sara Costa³, Mattia Bugatti¹, Stefano Calza⁵, Claudio Agostinelli⁶, Stefano Pileri⁷, Piera Balzarini¹, Alessandra Tucci⁸, Giuseppe Rossi⁸, Lara Furlani⁴, Giuseppe Todeschini⁴, Alberto Zamò⁹, Fabio Facchetti¹, Luisa Lorenzi^{1#}, Silvia Lonardi^{1#}, Marco A. Cassatella^{3*}

¹Section of Pathology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy;

²Department of Pathology and Immunology, Washington University, Saint Louis, MO, USA;

³Section of General Pathology, Department of Medicine, University of Verona, 37134 Verona, Italy;

⁴Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy;

⁵Unit of Biostatistics, Department of Molecular and Translational Medicine, University of Brescia, 25125 Brescia, Italy;

⁶Haematopathology Unit, Department of Experimental Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, 40137 Italy;

⁷Unit of Haematopathology, European Institute of Oncology, 20141 Milan, and Department of Experimental Diagnostic and Specialty Medicine, University of Bologna, 40137 Bologna, Italy;

⁸Division of Haematology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy;

⁹Section of Pathology, Department of Public Health and Diagnostics, University of Verona, 37134 Verona, Italy.

Supplementary Tables:

Supplementary Table S1 reports the content of slan⁺-cells in the lymph nodes of reactive lymphadenitis, as revealed by immunohistochemistry.

Supplementary Table S2 reports the content of slan⁺-cells in NHL, as revealed by immunohistochemistry.

Supplementary Table S3 shows the clinical and histological features of DLBCL patients belonging to cohort 2.

Supplementary Table S4 shows the clinical and histological features of DLBCL patients belonging to cohort 3.

Supplementary Table S5 lists all antibodies used for immunohistochemistry and flow cytometry stainings.

Supplementary Table S6 reports the clinical features of NHL patients from a prospective cohort whose lymph nodes and/or blood samples were available for phenotypic or functional analysis of slan⁺ cells.

Supplementary Table S7 reports the clinical features of DLBCL patients from a prospective cohort whose lymph nodes and/or blood samples were available for phenotypic or functional analysis of slan⁺ cells.

Supplementary Table S8 summarizes the correlation analysis among the clinical features and the expression of slan, CD16 or CD56. Data suggest that a high CD16 density correlates with advanced stage.

Supplementary Table S9 demonstrates that there is a lack of clinical significance, in term of survival probability, by CD16⁺, CD56⁺ or slan⁺ cell infiltration in DLBCL.

Supplementary Table S10 shows the clinical, pathology and molecular features of DLBCL samples infiltrated either by slan⁺-macrophages (slan⁺-MΦ) only, or by slan⁺-DCs only. No major differences are observed.

Supplementary Table S1. Frequency of slan⁺-cells in reactive lymphadenitis.

reactive lymphadenitis	number of cases	median age (year range)	gender (M;F)	slan ⁺ -cells (%)		
				0	1	2
Follicular hyperplasia	22	32.5 (3-72)	15;7	4 (18.2)	16 (72.7)	2 (9.1)
Dermatopathic Lymphadenitis	15	49 (9-81)	12;3	1 (6.7)	11 (73.3)	3 (20)
Infective granulomatous lymph adenitis (mycobacterial and toxoplasmic)*	15	38 (2-62)	7;8	7 (46.7)	5 (33.3)	3 (20)
Non infective granulomatous lymph adenitis (sarcoidosis)	15	44 (30-70)	6;9	2 (13.3)	10 (66.7)	3 (20)
Total	67	43 (2-81)	40;27	14 (20.9)	42 (62.7)	11 (16.4)

Supplementary Table S2. Frequency of slan⁺-cells in NHL screening cohort.

NHL-screening cohort	number of cases	slan ⁺ -cells (%)		
		0	1	2
B-cell lymphomas				
Chronic lymphocytic leukaemia / small lymphocytic lymphoma	10	10 (100)	0 (0)	0 (0)
Mantle cell lymphoma	8	4 (50)	4 (50)	0 (0)
Nodal Marginal zone lymphoma	10	8 (80)	1 (10)	1 (10)
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)	8	2 (25)	4 (50)	2 (25)
Follicular lymphoma	13	4 (31)	7 (54)	2 (15)
Burkitt Lymphoma	5	3 (60)	1 (20)	1 (20)
T-cell/histiocyte rich large B-cell lymphoma	9	3 (33)	5 (56)	1 (11)
Primary mediastinal (thymic) large B-cell lymphoma	11	5 (45)	5 (45)	1 (10)
Nodal DLBCL	15	3 (20)	7 (46.7)	5 (33.3)
Bone marrow localization of nodal DLBCL	9	2 (22.2)	6 (66.7)	1 (11.1)
Extranodal DLBCL	15	3 (20)	7 (47)	5 (33)
High grade B-cell lymphoma, with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements	12	5 (42)	3 (25)	4 (33)
Total NHBCL	125	52 (41.6)	50 (40)	23 (18.4)
T-cell lymphomas				
Peripheral T-cell lymphoma, NOS	5	2 (40)	2 (40)	1 (20)
Angioimmunoblastic T-cell lymphoma	10	3 (30)	4 (40)	3 (30)
Anaplastic large cell lymphoma, ALK-positive	5	4 (80)	0 (0)	1 (20)
Anaplastic large cell lymphoma, ALK-negative	6	3 (60)	2 (40)	1 (20)
Total NHTCL	26	12 (46.1)	8 (30.8)	6 (23.1)

Supplementary Table S3. Clinical and histological features, as well as scores for slan, CD16 and CD56 expression in DLBCL Cohort 2.

case	gender	age (years)	slan	CD16	CD56	BCL2	c-Myc	disease Stage	R-IPI score
1	F	69	0	2	0	1	0	IIIBs	3
2	M	91	0	2	0	1	1	IIIA	2
3	M	56	0	1	0	1	0	IVA	3
4	M	61	0	2	0	1	1	IVB	4
5	F	70	0	1	0	1	0	IVA	3
6	M	38	0	2	0	1	1	IA	1
7	F	74	0	1	0	1	0	IIIA	3
8	M	70	0	2	1	1	0	IIIB	3
9	M	68	0	2	0	1	1	IVA	3
10	F	72	0	1	0	0	1	IIIB	2
11	M	72	0	1	0	0	1	IVA	3
12	M	80	0	1	1	0	0	IVA	3
13	F	77	1	2	0	1	1	IVA	3
14	F	66	1	1	1	0	0	IIA	1
15	M	39	1	2	1	1	0	IVA	3
16	F	77	1	2	1	0	1	IIIA	3
17	M	77	0	2	0	1	0	IIA	1
18	F	79	0	2	0	0	1	IVA	3
19	F	37	1	0	0	0	0	IA	1
20	F	66	1	2	1	1	1	IIIB	2
21	M	47	1	2	0	0	1	IVB	3
22	M	60	1	2	0	0	1	IIIB	4
23	M	79	1	2	0	1	0	IIIAs	2
24	M	48	1	2	0	1	1	IIIA	3
25	F	49	1	2	0	0	1	IIIA	3
26	M	45	2	2	0	1	0	IIA	1
27	F	80	1	2	1	0	0	IIIA	3
28	F	36	2	2	0	0	0	IIA	1
29	M	64	2	2	0	1	1	IIIB	3
30	F	23	1	1	0	1	0	IA	1
31	F	76	1	2	1	1	0	IIIA	2
32	F	67	1	2	0	0	1	IIIB	3
33	M	63	2	2	0	0	0	IIIA	3
34	M	56	2	1	1	1	1	IVA	2
35	F	52	2	0	0	1	0	IVA	2
36	M	65	2	2	0	1	0	IVB	3
37	F	75	2	2	1	1	1	IIIA	3
38	F	72	1	2	0	1	0	IIIA	3
39	F	50	2	1	0	0	1	IVA	3
40	M	55	2	2	0	1	0	IIA	2
41	M	72	2	2	1	1	1	IVA	2
42	F	45	2	2	0	0	0	IVA	2
43	F	32	2	2	0	0	0	IIIA	3

Supplementary Table S4. Clinical and histological features, as well as scores for slan, CD16 and CD56 expression in DLBCL Cohort 3.

case	gender	age (years)	slan	CD16	CD56	BCL2	c-Myc	disease Stage	R-IPi score
1	F	68	0	1	0	1	0	IA	1
2	F	62	0	2	0	0	1	IIIB	4
3	F	70	0	2	0	1	1	III	3
4	F	65	0	2	0	0	0	IV	2
5	F	57	0	2	1	1	1	na	2
6	F	40	1	1	1	0	0	IA	0
7	F	75	1	2	0	1	0	IIA	2
8	M	65	1	2	1	1	1	III _s B	4
9	F	60	0	2	1	0	0	IIA	1
10	M	60	1	0	1	1	0	IVB	nd
11	F	62	1	0	1	0	0	IIA	1
12	F	61	1	0	1	1	1	IIEA	1
13	M	81	1	2	0	1	0	IIA	1
14	F	67	1	1	0	1	1	IIA	1
15	F	55	1	2	0	1	0	IIIB	3
16	F	75	1	1	1	1	0	IIIB	4
17	M	40	1	0	0	0	0	IIAE	1
18	F	77	1	0	1	0	1	IV	4
19	F	78	1	1	2	0	0	IV A E	3
20	F	70	1	2	0	1	1	IIA	1
21	M	43	1	0	0	0	1	III _s	3
22	F	77	2	1	2	1	0	IIIEA	2
23	F	45	1	1	0	1	1	IA	0
24	F	66	1	2	1	1	0	IIA	1
25	M	33	2	1	1	1	0	IA	0
26	F	80	2	0	0	1	1	III	3
27	M	81	2	0	0	0	1	na	3
28	M	51	1	2	1	0	0	IIIA	nd
29	F	76	2	1	0	1	1	IIA	2
30	F	81	2	1	1	1	0	IV _s A	nd
31	F	58	2	1	2	1	0	IIIA	2
32	F	59	2	2	0	1	1	IV	1
33	F	72	2	2	1	1	1	IVB	3
34	F	63	1	1	0	1	1	IVB	3
35	F	80	1	2	0	0	1	IIIA _s	3
36	M	78	2	2	1	1	1	IIIE	1
37	F	65	1	2	1	1	1	IV B	3
38	M	47	2	0	1	0	0	IIA	0
39	M	44	2	1	2	0	1	na	1
40	M	78	2	1	1	1	0	I	3
41	F	83	2	1	0	0	0	IVA	3
42	F	45	2	1	1	1	0	IVB	3
43	M	76	1	2	0	0	0	IV	3
44	M	74	2	2	1	0	1	IIIS	2
45	F	76	1	2	1	1	1	na	1
46	F	59	1	1	0	0	0	IVB	2
47	M	50	2	0	2	1	0	IIIA	2
48	F	82	1	2	1	1	1	IV _s A	4
49	M	36	2	0	2	0	0	IA	0
50	M	84	2	1	2	0	1	III B	3
51	M	56	2	0	1	1	0	IIA	0

Supplementary Table S5: Antibodies used for immunohistochemistry and flow cytometry

primary antibody	clone	dilution	isotype	source
immunohistochemical staining				
ALK / p80	5A4		mIgG1	Thermo Scientific
BCL2	124	1:300	mIgG1	Dako
BCL6	IG191E/A8	1:300	mIgG1	provided by G. Roncador
CCR7/CKR7	E271	1:600	rabbitIgG	Abcam
CD1a	010	1:50	mIgG1	Dako
CD3	SP7	1:100	rabbitIgG	Thermo Scientific
CD11c	5D11	1:50	mIgG2a	Leica Microsystems
CD14	7	1:50	mIgG2a	Leica Microsystems
CD16	2H7	1:100	mIgG2a	Leica Microsystems
CD20	L26	1:250	mIgG2a	Leica Microsystems
CD31	1A10	1:50	mIgG1	Leica Microsystems
CD56	123C3.D5	1:30	mIgG1	Thermo Scientific
CD66b	G10F5	1:200	mIgM	BioLegend
CD68	KP1	1:300	mIgG1	Dako
CD68	PG-M1	1:200	mIgG3	Dako
CD83	1H4b	1:150	mIgG1	Leica Microsystems
CD163	10D6	1:50	mIgG1	Thermo Scientific
CD208/DC-LAMP	104.G4	1:100	mIgG1	Immunotech
CD303/BDCA2	124B3.13	1:75	mIgG1	Dendritics
Caspase 3 Active		1:600	rabbit IgG	R&D Systems
c-Myc	Y69	1:50	rabbit IgG	Abcam
CSF1R	FER216	1:100	mIgG1	Millipore
DD2	DD2	1:50	mIgM	provided by K. Shackel
Lysozyme		1:1200	rabbit pAb	Dako
MDC8 FITC	DD1	1:60	mIgM	Miltenyi Biotec
MUM1	MUM1p	1:80	mIgG1	Dako
PAX-5	24/Pax-5	1:50	mIgG1	BD Biosciences
S100		1:3000	rabbit IgG	Dako
ZAP-70	2F3.2	1:50	mIgG2a	Cell Marque
flow cytometry staining (for antigen expression)				
mAbs	Clone		Isotype	Source
CD1c AlexaFluor647	L161		mIgG1	BioLegend
CD3 PE-Vio770	BW264/56		mIgG2a	Miltenyi Biotec
CD11b APC	ICRF44		mIgG1	BioLegend
CD11b PE	ICRF44		mIgG1	BioLegend
CD11c Vioblue	MJ4-27G12		mIgG2b	Miltenyi Biotec
CD14 PE	TÜK4		mIgG2a	Miltenyi Biotec
CD14 FITC	TÜK4		mIgG2a	Miltenyi Biotec
CD16 PE	3G8		mIgG1	BioLegend
CD16b PE	CLB-gran1 1.5		mIgG2a	BD Biosciences
CD19 PE-Vio770	LT19		mIgG1	Miltenyi Biotec
CD20 PE-Vio770	LT20		mIgG1	Miltenyi Biotec
CD32 PE	FUN-2		mIgG2b	BioLegend
CD40 PE	HB14		mIgG1	BioLegend
CD45 Brilliant Violet510	HI30		mIgG1	BioLegend
CD56 APC	AF12-7H3		mIgG1	Miltenyi Biotec
CD64 PE	10.1		mIgG1	BioLegend
CD80 PE	2D10		mIgG1	BioLegend
CD83 PE	HB15		mIgG1	Miltenyi Biotec
CD86 PE	IT2.2		mIgG2b	BioLegend
CD163 PE	GHI/61		mIgG1	BioLegend
CD303 FITC	AC144		mIgG1	Miltenyi Biotec
HLA-DR ACP/Cy7	L243		mIgG2a	BioLegend
MDC8 FITC	DD1		mIgM	Miltenyi Biotec
flow cytometry staining (for cell count)				
CD3 PE-Vio770	BW264/56		mIgG2a	Miltenyi Biotec
CD14 Vioblue	TÜK4		mIgG2a	Miltenyi Biotec
CD16 PerCP-Cy5.5	3G8		mIgG1	BioLegend
CD19 APC	LT19		mIgG1	Miltenyi Biotec
CD45 Brilliant Violet510	HI30		mIgG1	BioLegend

CD56 PE	AF12-7H3		mIgG1	Miltenyi Biotec
HLA-DR ACP/Cy7	L243		mIgG2a	BioLegend
MDC8 FITC	DD1		mIgM	Miltenyi Biotec

Supplementary Table S6. Clinical features of NHL patients.

Parameter	No.	(%)
Number of patients	18	
Gender		
Male	10	55.6
Female	8	44.4
Median Age (range)	63 (33-87)	
Age (years)		
< 60	7	38.9
≥ 60	11	61.1
Diagnosis		
DLBCL	9	50.0
FL	5	27.8
MZL	2	11.1
MCL	2	11.1
Clinical Stage		
I	2	11.1
II	6	33.3
III	3	16.7
IV	7	38.9
ECOG performance status		
0	4	22.2
1	6	33.3
2	3	16.7
3	2	11.1
4	1	5.6
Unknown	2	11.1
B symptoms		
Yes	4	22.2
No	14	77.8
Extranodal lesions		
≤ 1	17	94.4
≥ 2	0	0.0
Unknown	1	5.6
Bulky disease (> 10 cm)		
Yes	3	16.7
No	14	77.8
Unknown	1	5.6
Bone marrow involvement		
Yes	5	27.8
No	12	66.7
Unknown	1	5.6

Supplementary Table S7. Clinical features of DLBCL patients.

Parameter	No.	(%)
Number of patients	36	
Gender		
Male	21	58.3
Female	15	41.7
Median Age (range)	64 (31-86)	
Age (years)		
< 60	13	36.1
≥ 60	23	63.9
Clinical Stage		
I	4	11.1
II	3	8.3
III	15	41.7
IV	14	38.9
R-IPI		
0-2	16	44.4
3-5	20	55.6
B symptoms		
Yes	18	50.0
No	18	50.0
Extranodal lesions		
≤ 1	16	44.4
≥ 2	17	47.2
Unknown	3	8.3
Bulky disease (> 10 cm)		
Yes	12	33.3
No	24	66.7
Bone marrow involvement		
Yes	1	2.8
No	32	88.9
Unknown	3	8.3

Supplementary Table S8. DLBCL validation cohorts. Summary of parameters in DLBCL patients, with scores for slan, CD16 and CD56 expression (p calculated by Fisher Exact Tests; ANOVA for age). § Myc/Bcl2 double expressors vs others.

Parameters		Cohort # 2								Cohort #3								sum of Cohort #2 and #3										
		cases (%)	slan				CD16				cases (%)	slan				CD16				cases (%)	slan				CD16			
			0	1	2	p	0	1	2	p		0	1	2	p	0	1	2	p		0	1	2	p	0	1	2	P
All		43 (100)									51 (100)									94 (100)	28	41	25		14	28	52	
Male		21 (48.8)	9	6	6	0.40	0	4	17	0.31	18 (35.3)	2	9	7	0.18	8	4	6	0.04	39 (41.5)	11	15	13	0.46	8	8	23	0.18
Female		22 (51.2)	6	11	5		2	6	14		33 (64.7)	11	15	7		4	14	15		55 (58.5)	17	26	12		6	20	29	
Age		Average SD	67 14	62 17	52 14	0.07	44 11	62 17	62 16	0.31	Average SD	63 9	66 13	62 18	0.60	58 15	64 16	68 9	0.10	Average SD	65 12	65 15	58 17	0.14	56 15	63 16	65 15	0.14
Stage of disease at diagnosis	I	3 (7)	2	1	0	0.40	1	1	1	0.03	6 (11.8)	1	2	3	0.46	1	5	0	0.07	9 (9.6)	3	3	3	0.80	2	6	1	0.0096
	II	7 (16.3)	2	1	4		0	2	5		15 (29.4)	6	7	2		5	2	8		22 (23.4)	8	8	6		5	4	13	
	III	17 (39.5)	5	9	3		0	1	16		15 (29.4)	4	8	3		4	4	7		32 (34.0)	9	17	6		4	5	23	
	IV	16 (37.2)	6	6	4		1	6	9		15 (29.4)	2	7	6		2	7	6		31 (33.0)	8	13	10		3	13	15	
R-IP1 score	0	0 (0)	0	0	0	0.43	0	0	0	0.52	6 (11.8)	0	3	3	0.53	3	3	0	0.44	6 (6.4)	0	3	3	0.31	3	3	0	0.09
	1	7 (16.2)	3	2	2		1	2	4		13 (25.5)	5	5	3		3	3	7		20 (21.3)	8	7	5		4	5	11	
	2	10 (23.3)	3	2	5		1	2	7		9 (17.6)	3	4	2		1	4	4		19 (20.2)	6	6	7		2	6	11	
	3	24 (55.8)	8	12	4		0	6	18		15 (29.4)	2	8	5		2	8	5		39 (41.5)	10	20	9		3	12	24	
	4	2 (4.7)	1	1	0		0	0	2		5 (9.8)	0	0	0		0	0	0		7 (7.4)	3	4	0		1	1	5	
	nd	0 (0)	0	0	0		0	0	0		3 (5.9)	1	1	1		1	1	1		3 (3.2)	1	1	1		1	1	1	
BCL2 status (IHC)	-	17 (39.5)	4	9	4	0.30	1	5	11	0.64	20 (39.2)	4	11	5	0.71	7	6	7	0.33	37 (39.4)	8	20	9	0.25	8	11	18	0.31
	+	26 (60.5)	11	8	7		1	5	20		31 (60.8)	9	13	9		5	12	14		57 (60.6)	20	21	16		6	17	34	
MYC status (IHC)	-	23 (53.5)	8	8	7	0.69	2	6	15	0.49	27 (52.9)	8	10	9	0.34	7	12	8	0.18	50 (53.2)	16	18	16	0.26	9	18	23	0.16
	+	20 (46.5)	7	9	4		0	4	16		24 (47.1)	5	14	5		5	6	13		44 (46.8)	12	23	9		5	10	29	
MYC/BCL2	-/-	8 (18.6)	2	2	4	0.11 0.25§	1	2	5	0.64 0.35§	12 (23.5)	3	6	3	0.66 0.59§	4	4	4	0.37 0.15§	20 (21.3)	5	8	7	0.33 0.92§	5	6	9	0.31 0.07§
	+/-	9 (20.9)	2	7	0		0	3	6		8 (15.7)	1	5	2		3	2	3		17 (18.1)	3	12	2		3	5	9	
	-/+	15 (34.9)	6	6	3		1	4	10		15 (29.4)	5	4	6		3	8	4		30 (31.9)	11	10	9		4	12	14	
	+/+	11 (25.6)	5	2	4		0	1	10		16 (31.4)	4	9	3		2	4	10		27 (28.7)	9	11	7		2	5	20	
	0	15 (34.9)	15	0	0		1	6	8		13 (25.5)	13	0	0		3	2	8		28 (29.8)	28	0	0		4	8	16	
slan Score	1	17 (39.5)	0	17	0	-	0	3	14	0.19	24 (47.1)	0	24	0	-	6	8	10	0.20	41 (43.6)	0	41	0	-	6	11	24	0.93
	2	11 (25.6)	0	0	11		1	1	9		14 (27.4)	0	0	14		3	8	3		25 (26.6)	0	0	25		4	9	12	
	0	2 (4.6)	1	0	1		2	0	0		12 (23.5)	3	6	3		12	0	0		14 (14.9)	4	6	4		14	0	0	
CD16	1	10 (23.3)	6	3	1	0.19	0	10	0	-	18 (35.3)	2	8	8	0.20	0	18	0	-	28 (29.8)	8	11	9	0.93	0	28	0	-
	2	31 (72.1)	8	14	9		0	0	31		21 (41.2)	8	10	3		0	0	21		52 (55.3)	16	24	12		0	0	52	
	0	32 (74.4)	12	12	8		2	7	23		21 (41.2)	8	10	3		4	7	10		53 (56.4)	20	22	11		6	14	33	
CD56	1	11 (25.6)	3	5	3	0.91	0	3	8	1	23 (45.1)	5	11	7	0.15	6	6	11	0.12	34 (36.2)	8	16	10	0.13	6	9	19	0.02
	2	0 (0)	0	0	0		0	0	0		7 (13.7)	0	3	4		2	5	0		7 (7.4)	0	3	4		2	5	0	

Supplementary Table S9: Progression free survival (multivariate analysis).

variable	hazard ratio	confidence interval 95%	p value
<i>Multivariate</i>			
Stage	4.196	1.404-12.536	0.010
SSc ⁺	0.709	0.296-1.702	0.442
SSc ⁺⁺	0.652	0.239-1.783	0.405
CD16 ⁺	0.785	0.193-3.192	0.736
CD16 ⁺⁺	1.171	0.329-4.164	0.808
CD56 ⁺	2.246	1.023-4.928	0.044
CD56 ⁺⁺	1.607	0.296-8.716	0.582
<i>Univariate all listed estimates are adjusted for stage</i>			
R-IPi score	0.800	0.337-1.9	0.613
Myc ⁺	0.807	0.387-1.684	0.568
Bcl2 ⁺	1.263	0.592-2.692	0.546
Myc ⁺ /Bcl2 ⁺	1.015	0.412-2.504	0.974
slan score & CD16 ⁺ & CD56 ⁺	1.407	0.647-3.060	0.389
slan ⁺ -DCs vs slan ⁺ -macrophages	0.452	0.183-1.115	0.085

Supplementary Table S10: Clinical, pathology and molecular features of DLBCL samples infiltrated either by slan⁺-macrophages (slan⁺-MΦ) only or by slan⁺-DCs only

parameters		N cases (%)	slan ⁺ -MΦ		slan ⁺ -DCs		p
			n	%	n	%	
all		66 (100%)	21	100	45	100	
male		38 (57.6)	11	52.4	27	60	0.06
female		28 (42.4)	10	47.6	18	40	
age		Average SD	66.13 13.06		60.14 16.72		0.19
stage of disease at diagnosis	I	6 (9.1)	0	0.0	6	13.3	0.36
	II	14 (21.2)	5	23.8	9	20.0	
	III	23 (34.8)	9	42.9	14	31.1	
	IV	23 (34.8)	7	33.3	16	35.6	
IPI score	0	6 (9.1)	0	0.0	6	13.3	0.03
	1	12 (18.2)	4	19.0	8	17.8	
	2	13(19.7)	1	4.8	12	26.7	
	3	29 (43.9)	14	66.6	15	33.3	
	4	4 (6.1)	1	4.8	3	6.7	
	nd	2 (3)	1	4.8	1	2.2	
BCL2 status	-	29 (43.9)	11	53.4	18	40.0	0.43
	+	37 (56.1)	10	47.6	27	60.0	
MYC status	-	34 (51.5)	7	33.3	27	60.0	0.06
	+	32 (48.5)	14	66.7	18	40.0	
DEL	no DEL	48 (72.7)	14	66.7	34	75.6	0.56
	DEL	18 (27.3)	7	33.3	11	24.4	
slan score	0	0 (0)	0	0.0	0	0.0	0.17
	1	41 (62.1)	16	76.2	25	55.6	
	2	25 (37.9)	5	23.8	20	44.4	
CD16	0	10 (15.2)	1	4.8	9	20.0	0.06
	1	20 (30.3)	4	19.0	16	35.6	
	2	36 (54.5)	16	76.2	20	44.4	
CD56	0	33(50)	11	52.4	22	48.9	0.65
	1	26 (39.4)	9	42.8	17	37.8	
	2	7 (10.6)	1	4.8	6	13.3	